- Home
- CBAN vs CTNM Comparison
CBAN vs CTNM Comparison
Compare CBAN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBAN | CTNM |
|---|---|---|
| Founded | 1975 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 328.1M |
| IPO Year | 1998 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CBAN | CTNM |
|---|---|---|
| Price | $17.42 | $10.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 45.9K | ★ 185.2K |
| Earning Date | 01-21-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $122,550,000.00 | N/A |
| Revenue This Year | $20.97 | N/A |
| Revenue Next Year | $25.65 | N/A |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $13.99 | $3.35 |
| 52 Week High | $18.41 | $15.40 |
Technical Indicators
Market Signals| Indicator | CBAN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 48.61 |
| Support Level | $16.90 | $10.42 |
| Resistance Level | $17.46 | $11.14 |
| Average True Range (ATR) | 0.37 | 0.84 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 91.95 | 23.97 |
Price Performance
Historical ComparisonAbout CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.